JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 11, 2022 at 12:02: AM
via The healthcare conference's first day brought a trio of mRNA deals from Pfizer, a rare admission from Biogen's CEO and new focus on what's next in cell therapy.

article source
 

<



Similar threads

cafead
JPM22, Day 4: Vertex aims to be cystic fibrosis leader into the 2030s; Gritstone hopes for...
Replies
0
Views
125
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
JPM22, Day 3: In short order, Perrigo part of a new landscape; Legend, J&amp;J prep for...
Replies
0
Views
108
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
JPM22, Day 3: BeiGene, Ionis promise &#039;tidal wave&#039; of new drugs; Roche launches...
Replies
0
Views
167
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
JPM22, Day 2: Freenome passes $1B funding mark; Amgen spices things up with Arrakis; Sage...
Replies
0
Views
324
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
JPM22, Day 2: Sanofi&#039;s dealmaking priorities, bluebird&#039;s gene therapy goals and more
Replies
0
Views
107
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote